@NilavuMozhi @senthikraja Please read this https://t.co/sfMam3iC4W
@EpluribusAnders @msabouri @sdbaral @GYamey We could do more but Dengue vaccine work is being done and actually did have ADE as a complication. https://t.co/UDYWfo0SE4
@james_grist It's complex & @LanceTurtle knows more. 4 dengue serotypes (or 5 now!?) Re-exposure to same serotype: high affinity Ab neutralise virus. New exposure to 2nd serotype: Weakly cross-reactive (low affinity) Ab don't neut but help virus get in
New article: Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. https://t.co/6vxYLWXcjt
RT @mosquito_papers: Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. https://t.co/PoM5Fp4oUj
Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. https://t.co/PoM5Fp4oUj
@ISPM_ZOAP Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity https://t.co/CTU3oCkQ1v